GW Pharmaceuticals plc, a biopharmaceutical company, focuses on discovering, developing, and commercializing cannabinoid prescription medicines using botanical extracts derived from the Cannabis plant. Its lead product is Epidiolex, an oral medicine for the treatment of refractory childhood epilepsies, as well as for the treatment of Dravet syndrome, Lennox-Gastaut syndrome, tuberous sclerosis complex, and infantile spasms.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone44-12-2326-6800
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$12.74 million
Profitability
Miscellaneous
Employees791
Next Earnings Date11/5/2019 (Confirmed)
OptionableOptionable
GW Pharmaceuticals PLC- (NASDAQ:GWPH) Frequently Asked Questions
What is GW Pharmaceuticals PLC-'s stock symbol?
GW Pharmaceuticals PLC- trades on the NASDAQ under the ticker symbol "GWPH."
How were GW Pharmaceuticals PLC-'s earnings last quarter?
GW Pharmaceuticals PLC- (NASDAQ:GWPH) announced its earnings results on Tuesday, August, 6th. The biopharmaceutical company reported ($0.78) earnings per share for the quarter, beating analysts' consensus estimates of ($1.74) by $0.96. The biopharmaceutical company earned $72.04 million during the quarter, compared to analyst estimates of $37.28 million. GW Pharmaceuticals PLC- had a negative net margin of 101.45% and a negative return on equity of 38.09%. The company's quarterly revenue was up 2096.3% compared to the same quarter last year. During the same period in the previous year, the business earned ($0.25) EPS. View GW Pharmaceuticals PLC-'s Earnings History.
When is GW Pharmaceuticals PLC-'s next earnings date?
How can I listen to GW Pharmaceuticals PLC-'s earnings call?
GW Pharmaceuticals PLC- will be holding an earnings conference call on Tuesday, November 5th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.
What price target have analysts set for GWPH?
12 equities research analysts have issued 12 month price targets for GW Pharmaceuticals PLC-'s stock. Their predictions range from $185.00 to $238.00. On average, they expect GW Pharmaceuticals PLC-'s stock price to reach $215.00 in the next year. This suggests a possible upside of 76.5% from the stock's current price. View Analyst Price Targets for GW Pharmaceuticals PLC-.
What is the consensus analysts' recommendation for GW Pharmaceuticals PLC-?
12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for GW Pharmaceuticals PLC- in the last year. There are currently 12 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for GW Pharmaceuticals PLC-.
What are Wall Street analysts saying about GW Pharmaceuticals PLC- stock?
Here are some recent quotes from research analysts about GW Pharmaceuticals PLC- stock:
- 1. According to Zacks Investment Research, "GW Pharmaceuticals plc is a biopharmaceutical company focused on discovering, developing and commercializing therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. The Company's lead product, Sativex is used for the treatment of MS symptoms, cancer pain, and neuropathic pain. It operates primarily in the United Kingdom, Europe, the United States, Canada, and Asia. GW Pharmaceuticals plc is based in Salisbury, the United Kingdom. " (10/18/2019)
- 2. Cantor Fitzgerald analysts commented, ": We are reiterating our Overweight rating on GW Pharmaceuticals and raising our 12-month price target to $196/ADS from $193/ ADS following the announced sale of Voucher (PRV). As a reminder, GW Pharmaceuticals was awarded the PRV following the EPIDIOLEX approval last year. The recipient of the PRV was not announced in the press release." (3/18/2019)
Has GW Pharmaceuticals PLC- been receiving favorable news coverage?
Media coverage about GWPH stock has trended somewhat positive this week, InfoTrie Sentiment Analysis reports. InfoTrie rates the sentiment of media coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. GW Pharmaceuticals PLC- earned a media sentiment score of 0.8 on InfoTrie's scale. They also gave press coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the company's share price in the near future. View News Stories for GW Pharmaceuticals PLC-.
Are investors shorting GW Pharmaceuticals PLC-?
GW Pharmaceuticals PLC- saw a increase in short interest in September. As of September 30th, there was short interest totalling 4,470,000 shares, an increase of 12.6% from the August 30th total of 3,970,000 shares. Based on an average daily trading volume, of 577,800 shares, the short-interest ratio is currently 7.7 days. Approximately 14.6% of the company's stock are short sold. View GW Pharmaceuticals PLC-'s Current Options Chain.
Who are some of GW Pharmaceuticals PLC-'s key competitors?
Some companies that are related to GW Pharmaceuticals PLC- include UCB (UCBJF), GRIFOLS S A/S (GRFS), Genmab A/S (GNMSF), BioMarin Pharmaceutical (BMRN), Array Biopharma (ARRY), Mylan (MYL), Elanco Animal Health (ELAN), Ono Pharmaceutical (OPHLF), Alnylam Pharmaceuticals (ALNY), GALAPAGOS NV/S (GLPG), Teva Pharmaceutical Industries (TEVA), Bausch Health Companies (BHC), Ionis Pharmaceuticals (IONS), Perrigo (PRGO) and Catalent (CTLT).
What other stocks do shareholders of GW Pharmaceuticals PLC- own?
Who are GW Pharmaceuticals PLC-'s key executives?
GW Pharmaceuticals PLC-'s management team includes the folowing people:
- Dr. Geoffrey W. Guy BSc, LMSSA, Dip Pharm Med, MB BS, MRCS Eng, LRCP, Founder & Chairman (Age 65)
- Mr. Justin D. Gover, CEO & Exec. Director (Age 48)
- Mr. Scott M. Giacobello, Chief Financial Officer (Age 49)
- Mr. Douglas B. Snyder, Chief Legal Officer (Age 55)
- Mr. Julian S. Gangolli, U.S. Chief Commercial Officer (Age 61)
Who are GW Pharmaceuticals PLC-'s major shareholders?
GW Pharmaceuticals PLC-'s stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Rothschild Investment Corp IL (0.06%), Lake Street Financial LLC (0.02%), Henry James International Management Inc. (0.02%), North Star Investment Management Corp. (0.01%), Stephens Inc. AR (0.01%) and Enlightenment Research LLC (0.01%). Company insiders that own GW Pharmaceuticals PLC- stock include Adam D George, Cabot Brown, Catherine J Mackey, Christopher J Tovey, Douglas B Snyder, Geoffrey W Dr Guy, James Noble, Julian S Gangolli, Justin D Gover, Scott M Giacobello, Volker Knappertz and William A Waldegrave. View Institutional Ownership Trends for GW Pharmaceuticals PLC-.
Which major investors are selling GW Pharmaceuticals PLC- stock?
GWPH stock was sold by a variety of institutional investors in the last quarter, including Exane Derivatives, Coastal Investment Advisors Inc., Envestnet Asset Management Inc. and Financial Gravity Wealth Inc.. Company insiders that have sold GW Pharmaceuticals PLC- company stock in the last year include Adam D George, Cabot Brown, Catherine J Mackey, Christopher J Tovey, Douglas B Snyder, Geoffrey W Dr Guy, James Noble, Julian S Gangolli, Justin D Gover, Scott M Giacobello, Volker Knappertz and William A Waldegrave. View Insider Buying and Selling for GW Pharmaceuticals PLC-.
Which major investors are buying GW Pharmaceuticals PLC- stock?
GWPH stock was bought by a variety of institutional investors in the last quarter, including North Star Investment Management Corp., Henry James International Management Inc., Enlightenment Research LLC, Rothschild Investment Corp IL, Stephens Inc. AR, Lake Street Financial LLC, Valeo Financial Advisors LLC and Signaturefd LLC. View Insider Buying and Selling for GW Pharmaceuticals PLC-.
How do I buy shares of GW Pharmaceuticals PLC-?
Shares of GWPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is GW Pharmaceuticals PLC-'s stock price today?
One share of GWPH stock can currently be purchased for approximately $121.84.
How big of a company is GW Pharmaceuticals PLC-?
GW Pharmaceuticals PLC- has a market capitalization of $3.76 billion and generates $12.74 million in revenue each year. The biopharmaceutical company earns $-295,160,000.00 in net income (profit) each year or ($10.56) on an earnings per share basis. GW Pharmaceuticals PLC- employs 791 workers across the globe.View Additional Information About GW Pharmaceuticals PLC-.
What is GW Pharmaceuticals PLC-'s official website?
How can I contact GW Pharmaceuticals PLC-?
GW Pharmaceuticals PLC-'s mailing address is SOVEREIGN HOUSE VISION PARK HISTON, CAMBRIDGE X0, CB24 9BZ. The biopharmaceutical company can be reached via phone at 44-12-2326-6800 or via email at [email protected]
MarketBeat Community Rating for GW Pharmaceuticals PLC- (NASDAQ GWPH)
MarketBeat's community ratings are surveys of what our community members think about GW Pharmaceuticals PLC- and other stocks. Vote "Outperform" if you believe GWPH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GWPH will underperform the S&P 500 over the long term. You may vote once every thirty days.
